A clinical investigator in Poway, Calif., received an FDA Warning Letter May 27 for allegedly failing to ensure that the investigation was conducted according to the investigational plan (21 C.F.R. §312.60). According to the letter, which was posted by the FDA on June 14, the investigational plan for one protocol required the investigator to ensure that subjects randomized to... Read More